ClinicalTrials.gg
RecruitingNCT06069817HiSTENTUpdated Feb 13, 2024

Impact of High Flow Therapy on Complications Related to Airway Stenting

An interventional study of High flow nasal cannula and nebulized normal saline in Airway Obstruction, Respiratory Infection and Mucus; Plug, sponsored by Cardarelli Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Cardarelli Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The application of HFNC therapy in patients with airway stent, improving both humidification and clearance of the airway secretion, could potentially reduce the risk of mucoid impaction, respiratory infections and granulation. HFNC therapy could be superior to nebulization of normal saline (usual care) in order to keep the stent cleaned, reducing, by inference, the risk of complications, as defined above.

02

Conditions studied

  • Airway Obstruction
  • Respiratory Infection
  • Mucus; Plug

Keywords

  • high flow nasal cannula
  • airway stent
  • nebulized saline
03

In context

Airway Obstruction

148 studies on the registry are indexed under Airway Obstruction; 26 are open to participants now.

This study's planned enrollment of 30 is below the median of 52 across 93 interventional studies indexed under Airway Obstruction.

Browse Airway Obstruction studies →

Lead sponsor

Cardarelli Hospital is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Central Airway obstruction, both malignant and nonmalignant, treated with airway stenting (silicone or fully covered metallic stent)

Exclusion criteria

Exclusion Criteria:

  • to HFNC (recent - within 3 months - nose surgery or facial trauma)
  • Lack of written
  • Neuropsychiatric disorders
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High flow nasal cannula group

    Treatment with High Flow Nasal Cannula minimum twenty (20) minutes three times a day (one \[1\] hour a day in total) and up to 10 hours a day in total, according to patient's preferences.

    Device: High flow nasal cannula

  • Active comparator
    nebulized saline group

    Treatment with nebulization of 4-8 cc of normal saline three times daily

    Device: nebulized normal saline

Interventions

  • DeviceHigh flow nasal cannula

    home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction

  • Devicenebulized normal saline

    home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction

06

What researchers measure

Primary outcomes

  1. incidence of mucous plugging associated with airway stent in HFNC group

    mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 7 days from stent placement

  2. incidence of mucous plugging associated with airway stent in HFNC group

    mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 30 days from stent placement

  3. incidence of mucous plugging associated with airway stent in HFNC group

    mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 60 days from stent placement

  4. incidence of mucous plugging associated with airway stent in HFNC group

    mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 90 days from stent placement

  5. incidence of mucous plugging associated with airway stent in nebulized saline group

    mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 7 days from stent placement

  6. incidence of mucous plugging associated with airway stent in nebulized saline group

    mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 30 days from stent placement

  7. incidence of mucous plugging associated with airway stent in nebulized saline group

    mucous plugging assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 60 days from stent placement

  8. incidence of granuloma associated with airway stent in HFNC group

    granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 90 days from stent placement

  9. incidence of granuloma associated with airway stent in nebulized saline group

    granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 7 days from stent placement

  10. incidence of granuloma associated with airway stent in nebulized saline group

    granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 30 days from stent placement

  11. incidence of granuloma associated with airway stent in nebulized saline group

    granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 60 days from stent placement

  12. incidence of granuloma associated with airway stent in nebulized saline group

    granuloma formation assessed during bronchoscopy, eventually determining reduction in cross-sectional stent area

    Time frame: within 90 days from stent placement

  13. incidence of respiratory infection associated with airway stent in HFNC group

    symptoms of respiratory infection + radiologic and/or bronchoscopic signs of infection + need of antibiotic therapy

    Time frame: within 90 days from stent placement

  14. incidence of respiratory infection associated with airway stent in nebulized saline group

    symptoms of respiratory infection + radiologic and/or bronchoscopic signs of infection + need of antibiotic therapy

    Time frame: within 90 days from stent placement

Secondary outcomes

  1. adherence to home treatment with HFNC in patients with airway stent, as assesed by time of daily utilization

    minutes a day spent on HFNC

    Time frame: within 90 days from stent placement

  2. adherence to home treatment with nebulization of normal saline in patients with airway stent, as assesed by time of daily utilization

    times a day spent on nebulization

    Time frame: within 90 days from stent placement

  3. incidence of adverse events due to home treatment with HFNC in patients with airway stent

    incidence of malfunction of the device; incidence of complications as assessed by clinical examination (cough, headache, rhinitis)

    Time frame: within 90 days from stent placement

  4. incidence of adverse events due to home treatment with nebulization of normal saline in patients with airway stent

    incidence of malfunction of the device; incidence of complications as assessed by clinical examination (cough, headache, rhinitis)

    Time frame: within 90 days from stent placement

  5. Satisfaction of home treatment with HFNC by Cough and sputum assessment questionnaire (CASA-Q)

    Cough and sputum assessment questionnaire (CASA-Q) to evaluate both severity of cough and sputum production to quality of life impairment (minimum value 0, maximum value 100; higher scores mean worse outcome)

    Time frame: within 90 days from stent placement

  6. Satisfaction of home treatment with nebulized saline by Cough and sputum assessment questionnaire CASA-Q

    Cough and sputum assessment questionnaire (CASA-Q) to evaluate both severity of cough and sputum production to quality of life impairment (minimum value 0, maximum value 100; higher scores mean worse outcome)

    Time frame: within 90 days from stent placement

  7. incidence of airway stent colonization in HFNC group

    positive bronchial aspirate culture

    Time frame: within 90 days from stent placement

  8. incidence of airway stent colonization in nebulized saline group

    positive bronchial aspirate culture

    Time frame: within 90 days from stent placement

  9. all cause-mortality in HFNC group

    Time frame: within 90 days from stent placement

  10. all cause-mortality in nebulized saline group

    Time frame: within 90 days from stent placement

  11. mortality due to respiratory infection in HFNC group

    Time frame: within 90 days from stent placement

  12. mortality due to respiratory infection in nebulized saline group

    Time frame: within 90 days from stent placement

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2024, 10 months after the start.

Of 36 non-industry interventional studies with no phase under Airway Obstruction, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 37. This study's planned 10 months is below that.

Counting every sponsor, half of 44 studies reached it within 16 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 6, 2023
StartActual
Jan 1, 2024
Primary completionEst.
Nov 1, 2024
CompletionEst.
Dec 31, 2024
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06069817
Lead sponsor
Cardarelli Hospital
Responsible party
Giuseppe Failla (Chief of Interventional Pulmonology Unit, Cardarelli Hospital) — Principal investigator
First posted
Oct 6, 2023
Start date
Jan 1, 2024
Primary completion
Nov 1, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Feb 13, 2024

Study contacts

Nadia Corcione, MD, PhD
Contact
nadia.corcione@gmail.com
+ 39 0817473393
Giuseppe Failla, MD
study director · Ospedale "Antonio Cardarelli", Naples
Nadia Corcione, MD, PhD
principal investigator · Ospedale "Antonio Cardarelli", Naples
Alfonso Pecoraro, MD
principal investigator · Ospedale "Antonio Cardarelli", Naples

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion